Ionis faces shareholder investigation over guidance cut
Alpha Vantage · Morningstar · · AI-summarised by FinFlash
SueWallSt is investigating Ionis Pharmaceuticals on behalf of investors who lost money after the company cut full-year TRYNGOLZA sales guidance by more than 50% on November 9, 2026, despite beating third-quarter revenue estimates. The reduction triggered a sharp share decline and questions about statements made before the disclosure.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.